Abstract
BackgroundBrain-derived neurotrophic factor (BDNF) exerts beneficial effects not only on diabetic neuropathies but also on cardiovascular injury. There is argument regarding the levels of serum BDNF in patients with diabetes mellitus (DM). Because BDNF in peripheral blood is rich in platelets, this may represent dysregulation of BDNF release from platelets. Here we focused on advanced glycation end products (AGEs), which are elevated in patients with DM and have adverse effects on cardiovascular functions. The aim of this study is to elucidate the role of AGEs in the regulation of BDNF release from human platelets.MethodsPlatelets collected from peripheral blood of healthy volunteers were incubated with various concentrations of AGE (glycated-BSA) at 37 °C for 5 min with or without BAPTA-AM, a cell permeable Ca2+ chelator, or PP2, a potent inhibitor of Src family kinases (SFKs). Released and cellular BDNF were measured by ELISA and calculated. Phosphorylation of Src and Syk, a downstream kinase of SFKs, in stimulated platelets was examined by Western blotting and immunoprecipitation.ResultsAGE induced BDNF release from human platelets in a dose-dependent manner, which was dependent on intracellular Ca2+ and SFKs. We found that AGE induced phosphorylation of Src and Syk.ConclusionsAGE induces BDNF release from human platelets through the activation of the Src-Syk-(possibly phospholipase C)-Ca2+ pathway. Considering the toxic action of AGEs and the protective roles of BDNF, it can be hypothesized that AGE-induced BDNF release is a biological defense system in the early phase of diabetes. Chronic elevation of AGEs may induce depletion or downregulation of BDNF in platelets during the progression of DM.
Highlights
Brain-derived neurotrophic factor (BDNF) exerts beneficial effects on diabetic neuropathies and on cardiovascular injury
To analyze the dynamics of acute BDNF release from platelets under physiological conditions, we examined the effect of advanced glycation end product (AGE) on BDNF release from platelets of healthy control participants and analyzed their signaling mechanisms
The contents in each fraction varied greatly among participants, the ratio of BDNF release from platelets was rather constant as shown in Fig. 1
Summary
Brain-derived neurotrophic factor (BDNF) exerts beneficial effects on diabetic neuropathies and on cardiovascular injury. The association of blood BDNF levels with cardiovascular diseases, such as angina pectoris [13] and heart failure [14, 15] were reported, with lower levels of BDNF being associated with the risk of cardiovascular diseases. These effects must come from outside of the CNS, presumably from BDNF in blood. The mechanism of this inconsistency remains unclear blood glucose levels, duration of DM, medications, gender, etc., may play a role
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.